Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

315.29 +7.73 (+2.51%)
Streaming Delayed Price Updated: 12:50 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance ↗
 
Via Benzinga
News headline image
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
News headline image
Recap: Insulet Q2 Earnings ↗
Insulet (NASDAQ:PODD) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Insulet missed estimated earnings by... 
Via Benzinga
News headline image
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)
From Insulet Corporation
Via Business Wire
News headline image
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System
From Insulet Corporation
Via Business Wire
News headline image
5 Analysts Have This to Say About Insulet ↗
Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
4 Analysts Have This to Say About Insulet ↗
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
News headline image
Expert Ratings for Insulet ↗
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings: 
Via Benzinga
News headline image
Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022
From Insulet Corporation
Via Business Wire
News headline image
7 Stocks to Buy That Could Make You a Millionaire ↗
These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments. 
Via InvestorPlace
News headline image
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close ↗
The health and wellness industry focused on the well-being of the body, mind and spirit has captured the globe's attention. According to management consulting firm, Mckinsey & Co., the global wellness... 
Via Benzinga
News headline image
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
From Insulet Corporation
Via Business Wire
News headline image
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
News headline image
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
News headline image
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks ↗
The deal would have been transformative, but may have limited teamwork in the space. 
Via Investor's Business Daily
News headline image
Looking Into Insulet's Return On Capital Employed ↗
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4. 
Via Benzinga
News headline image
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space ↗
One analyst called the rumored deal "transformative," but says the timing is unfavorable. 
Via Investor's Business Daily
News headline image
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition ↗
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. 
Via InvestorPlace
News headline image
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ↗
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning! 
Via InvestorPlace
News headline image
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know ↗
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
News headline image
Recap: Insulet Q1 Earnings ↗
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by... 
Via Benzinga
News headline image
Insulet Announces CEO Transition
From Insulet Corporation
Via Business Wire
News headline image
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
News headline image
Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
News headline image
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes ↗
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with... 
Via Benzinga
News headline image
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
From Insulet Corporation
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.